CML patients can now be treated at home

The US FDA has just approved the home administration of Teva’s Synribo (omacetaxine mepesuccinate). Physicians who treat adults with chronic or accelerated phase Chronic Myeloid Leukemia (CML) can now administer Synribo therapy in the patient’s own home.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *